secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001213900-24-060093
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center
--------------------------------------------------------------------------------

- IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.
- Goal is to confirm 80% cure rate (30-100% CI) from Yale April 2024 case series published in Clinical Infectious Diseases.
- Three-part program: acute hospitalized (enrolling), expanded access (announced), and chronic babesiosis (planned, gated by NC State study).
- Company plans to file NDA for supplemental babesiosis indication by Q2 2026.
- U.S. accessible market estimate: 38,000 acute immunosuppressed patients and at least 375,000 chronic babesiosis patients through 2035.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024060093/0001213900-24-060093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024060093/ea0209161-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-060093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer